Last edition
News about "Idiopathic Pulmonary Fibrosis (IPF) "
Simcere Pharmaceutical and Stanford Medicine Partner on IPF Therapy Research
Simcere Pharmaceutical has entered a research collaboration with Stanford Medicine to develop innovative therapies for Idiopathic Pulmonary Fibrosis (IPF).
Idiopathic Pulmonary Fibrosis (IPF) | 16/06/2026 | By News Bureau
Jascayd is the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B) to be approved in this indication. This represents a novel mechanism of action that exerts both antifibrotic and immunomodulatory effects, thereby slowing the decline in lung function in IPF patients.
Idiopathic Pulmonary Fibrosis (IPF) | 10/10/2025 | By Dineshwori | 475
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy